Axatilimab

Specification

• Cat#: THA-0149
• Product Name: Axatilimab
• Description: Axatilimab is a monoclonal antibody targeting CSF-1R to reduce pathogenic macrophage activity in patients with chronic graft-versus-host disease.
• Sequences: axatilimab_heavy_chain: EVTLKESGPALVKPTQTLTLTCTFSGFSLTTYGMGVGWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIGPIKYPTAPYRYFDFWGQGTMVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK axatilimab_light_chain: DIQMTQSPSSLSASVGDRVTITCLASEDIYDNLAWYQQKPGKAPKLLIYYASSLQDGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCLQDSEYPWTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
• Molecular Weight: 150000.0 Da
• Introduction: Axatilimab is a humanized IgG4 monoclonal antibody produced in Chinese hamster ovary cells. It is targeted against macrophage colony-stimulating factor 1 receptor (CSF-1R), causing a reduction in circulating levels of monocytes and macrophages responsible for the symptoms associated with chronic graft-versus-host disease (cGVHD). The mainstay of cGVHD treatment are systemic corticosteroids, but they are ineffective in 30-50% of cases. Approved treatment options in steroid-refractory cGHVD are limited, and include ruxolitinib, ibrutinib, and belumosudil. Axatilimab was approved by the FDA in August 2024 for the third-line treatment of cGVHD. It is the first FDA-approved anti-CSF-1R antibody directed against inflammatory and fibrotic drivers in chronic graft-versus-host disease.
• Purity: >99% by SDS-Page and HPLC analysis
• Formula: Not Available
• Appearance: Liquid
• Endotoxin Level: < 0.001 EU/μg of the protein by the LAL method

Pharmaceutical Information

• Pharmacodynamics: The administration of axatilimab results in a dose-dependent increase in CSF-1 and interleukin-34 concentrations and a dose-dependent reduction in peripheral blood non-classical monocytes.
• Targets: Macrophage colony-stimulating factor 1 receptor